Emory University: Investigational Drug for Genetic Form of ALS Showing Early Promise, Trial Indicates
July 25, 2020
July 25, 2020
ATLANTA, Georgia, July 25 -- Emory University's Woodruff Health Sciences Center issued the following news release:
An experimental gene-silencing drug designed for a rare, inherited form of amyotrophic lateral sclerosis (ALS) has shown promise in a clinical trial conducted at the Emory ALS Center and other medical centers around the world.
The trial indicated that the "antisense" drug, known as tofersen, lowers levels of a disease-causing protein in peopl . . .
An experimental gene-silencing drug designed for a rare, inherited form of amyotrophic lateral sclerosis (ALS) has shown promise in a clinical trial conducted at the Emory ALS Center and other medical centers around the world.
The trial indicated that the "antisense" drug, known as tofersen, lowers levels of a disease-causing protein in peopl . . .